Corxel Pharmaceuticals Secures Up to $287M in Series D1 Funding for Cardiometabolic Therapies

Corxel Pharmaceuticals Limited has been stacking weight quietly for years, and on January 22, 2026, it finally stepped on the scale. The Berkeley Heights, New Jersey based clinical stage biopharma closed a Series D1 financing of up to $287M, a number that carries authority because of where Corxel came from and where it is clearly headed. Founded in 2019 through an incubation partnership with RTW Investments, the company began as Ji Xing Pharmaceuticals before rebranding in 2024 to signal something larger than geography. This is no longer a China story or a US story. This is a global cardiometabolic platform with real capital behind it.

The D1 round drew a syndicate that reads like a closed room at JPM Healthcare. SR One Capital Management, TCG Crossover, and RA Capital Management led, joined by HBM Healthcare, SymBiosis, Adage Capital, Invus, SilverArc Capital, and others, with RTW Investments and Hengdian Group Capital returning. Three new board seats came with the round, and the message was direct. This is execution capital. Combined with the $162M Series D in 2024, which included a $35M strategic investment from Bayer, Corxel has raised more than $449M across D and D1 alone. That kind of balance sheet changes posture.

At the center is CX11, a once daily oral small molecule GLP-1 receptor agonist for obesity and Type 2 diabetes. Oral matters. No injections. No theatrics. In China Phase 2 data presented at the American Diabetes Association Scientific Sessions in June 2025, CX11 delivered up to 9.7% mean body weight reduction at week 16 with favorable tolerability. In the US, a 250 patient Phase 2 obesity study is underway, with first patient dosed June 17, 2025 and topline data expected in the first half of 2026. A global Phase 2 Type 2 diabetes program is next, now FDA cleared and funded by this round.

Corxel is not a single asset story. JX10 targets acute ischemic stroke with a pro thrombolytic and anti-inflammatory approach. JX09 addresses hypertension as a selective aldosterone synthase inhibitor. In Greater China, the company already markets an approved varenicline solution nasal spray for dry eye disease, alongside late stage ophthalmology and cardiology programs. This is a pipeline built around cardiometabolic reality, not trend cycles.

Leadership has been steady. Sandy Mou, Board Executive Director and CEO, guided the transition from incubated platform to global operator. Kevin Xie joined as CFO in February 2025 after steering Gracell Biotechnologies through a $1.2B acquisition. Christine Dai, Chief Human Resources Officer, has been building the organizational spine needed for multiregional trials and late stage execution. This is infrastructure thinking, not headline chasing.

Corxel is an apt name. Dense at the core, layered with science, capital, and timing. With US Phase 2 data approaching and capital in place to push toward Phase 3, the question is no longer whether Corxel belongs in the cardiometabolic conversation. The question is how loud that conversation becomes once the data starts speaking.